{"id":"modified-hit-skk-cycle-b4-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HIT-SKK refers to a multi-agent chemotherapy protocol used primarily in pediatric oncology. The 'Modified' designation and 'Cycle B4-5' notation indicate this is a specific treatment block within a larger protocol, likely combining agents such as methotrexate, cytarabine, doxorubicin, and other alkylating or antimetabolite drugs. The regimen works by inducing apoptosis in rapidly dividing malignant cells through multiple mechanisms of DNA damage and cell cycle arrest.","oneSentence":"Modified HIT-SKK Cycle B4-5 is a chemotherapy regimen combining multiple cytotoxic agents designed to treat pediatric hematologic malignancies through cell cycle disruption and DNA damage.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:10.537Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric acute lymphoblastic leukemia (ALL)"},{"name":"Pediatric acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Modified HIT-SKK Cycle B4-5","genericName":"Modified HIT-SKK Cycle B4-5","companyName":"Nationwide Children's Hospital","companyId":"nationwide-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Modified HIT-SKK Cycle B4-5 is a chemotherapy regimen combining multiple cytotoxic agents designed to treat pediatric hematologic malignancies through cell cycle disruption and DNA damage. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}